{"id":"fludarabine-busulfan-thymoglobulin","safety":{"commonSideEffects":[{"rate":"20-50%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-15%","effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL820","moleculeType":"Small molecule","molecularWeight":"246.31"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Fludarabine works by incorporating itself into DNA and interfering with DNA synthesis, leading to cell death. Busulfan works by cross-linking DNA, which prevents cancer cells from replicating. Thymoglobulin works by binding to CD3 receptors on T-lymphocytes and marking them for destruction, leading to a decrease in T-cell count.","oneSentence":"Fludarabine is a purine analog that interferes with DNA synthesis, Busulfan is an alkylating agent that cross-links DNA, and Thymoglobulin is a monoclonal antibody that depletes T-lymphocytes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:00:19.516Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia, Chronic lymphocytic leukemia, Kidney transplant rejection"}]},"trialDetails":[{"nctId":"NCT04644016","phase":"PHASE2","title":"Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-11-20","conditions":"AML, ALL, MDS","enrollment":31},{"nctId":"NCT06872333","phase":"PHASE2","title":"Allo HSCT for High Risk Hemoglobinopathies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-11-19","conditions":"Graft Failure, Sickle Cell Disease, Hemoglobinopathies","enrollment":62},{"nctId":"NCT06158828","phase":"PHASE1, PHASE2","title":"Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-05-15","conditions":"AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric","enrollment":68},{"nctId":"NCT05917405","phase":"PHASE2","title":"Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2023-09-14","conditions":"Acute Myeloid Leukemia in Remission","enrollment":302},{"nctId":"NCT06252870","phase":"PHASE2","title":"Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-07-18","conditions":"Graft Versus Host Disease, Hematologic Malignancy","enrollment":82},{"nctId":"NCT03121014","phase":"PHASE2","title":"Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2017-04-24","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":38},{"nctId":"NCT05457556","phase":"PHASE3","title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-03-15","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":435},{"nctId":"NCT02143830","phase":"PHASE2","title":"HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2014-04","conditions":"Fanconi Anemia, Severe Marrow Failure, Myelodysplastic Syndrome (MDS)","enrollment":70},{"nctId":"NCT05579769","phase":"PHASE2","title":"Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-03-14","conditions":"Hematologic Malignancy, Myeloid Malignancy","enrollment":3},{"nctId":"NCT02512497","phase":"PHASE1","title":"Romidepsin Maintenance After Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2017-12-08","conditions":"Cutaneous T-cell Lymphoma, T-Prolymphocytic Leukemia, T-Large Granulocytic Leukemia","enrollment":23},{"nctId":"NCT04872595","phase":"PHASE2","title":"A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-04-30","conditions":"Acute Myeloid Leukemia (AML), Acute Lymphoid Leukemia (ALL), Myelodysplastic Syndromes (MDS)","enrollment":59},{"nctId":"NCT01461837","phase":"PHASE2","title":"Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"New York Medical College","startDate":"2012-01","conditions":"Sickle Cell Disease","enrollment":21},{"nctId":"NCT05735717","phase":"PHASE2","title":"MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-05-11","conditions":"Hematologic Malignancy, Acute Leukemia, Remission","enrollment":70},{"nctId":"NCT03456817","phase":"PHASE2","title":"HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2020-07-01","conditions":"Graft-versus-host-disease, Relapse","enrollment":68},{"nctId":"NCT03597594","phase":"PHASE1, PHASE2","title":"Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2021-09-02","conditions":"Severe Combined Immunodeficiency","enrollment":4},{"nctId":"NCT01985061","phase":"PHASE2","title":"Evaluation of 3 Different Doses of IV Busulfan","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Paoli-Calmettes","startDate":"2013-12","conditions":"Myelodysplastic Syndrome, Acute Myeloid Leukemia","enrollment":177},{"nctId":"NCT02928991","phase":"EARLY_PHASE1","title":"Fludarabine Based RIC for Bone Marrow Failure Syndromes","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2015-04","conditions":"Bone Marrow Failure Syndromes","enrollment":25},{"nctId":"NCT06869265","phase":"PHASE2","title":"Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-05-01","conditions":"Acute Myeloid Leukemia (AML), High Risk Acute Myeloid Leukemia(AML), Relapsed/Refractory Acute Myeloid Leukemia (AML)","enrollment":56},{"nctId":"NCT02766465","phase":"PHASE2","title":"Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-03-16","conditions":"Sickle Cell Disease","enrollment":138},{"nctId":"NCT03615105","phase":"PHASE2","title":"Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-07-25","conditions":"Acute Lymphoid Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML)","enrollment":9},{"nctId":"NCT04547049","phase":"PHASE3","title":"A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2020-09-01","conditions":"Leukemia","enrollment":176},{"nctId":"NCT01758328","phase":"PHASE1","title":"Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12","conditions":"Multiple Myeloma","enrollment":29},{"nctId":"NCT06741813","phase":"NA","title":"Allo-HSCT vs ASCT in Adult T-LBL","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-01-01","conditions":"T Lymphoblastic Lymphoma","enrollment":230},{"nctId":"NCT01019876","phase":"PHASE2, PHASE3","title":"Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases","status":"COMPLETED","sponsor":"Columbia University","startDate":"2002-09","conditions":"Bone Marrow Failure, Osteopetrosis, Fanconi Anemia","enrollment":38},{"nctId":"NCT04776850","phase":"EARLY_PHASE1","title":"Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-12-29","conditions":"Beta Thalassemia Major, Sickle Beta 0 Thalassemia, Sickle Beta Plus Thalassemia","enrollment":""},{"nctId":"NCT02582775","phase":"PHASE2","title":"MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2016-03","conditions":"Epidermolysis Bullosa","enrollment":17},{"nctId":"NCT06571825","phase":"PHASE4","title":"RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR","status":"RECRUITING","sponsor":"He Huang","startDate":"2024-07-17","conditions":"Acute Myeloid Leukemia","enrollment":118},{"nctId":"NCT04009525","phase":"PHASE4","title":"Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study","status":"COMPLETED","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2019-07-05","conditions":"Thalassemia Major","enrollment":823},{"nctId":"NCT03079089","phase":"NA","title":"Sequential Conditioning in Haploidentical Transplantation for Hematopoietic Stem Cells in Patients With Relapsed or Refractory Lymphoid Hematological Disorders","status":"COMPLETED","sponsor":"Association for Training, Education, and Research in Hematology, Immunology, and Transplantation","startDate":"2017-06-30","conditions":"Refractory or Relapsed Lymphoid Haemopathy","enrollment":40},{"nctId":"NCT03412409","phase":"PHASE2","title":"RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2018-02-01","conditions":"Acute Leukemia, Myelodysplastic Syndromes","enrollment":50},{"nctId":"NCT02441803","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-14","conditions":"Leukemia","enrollment":11},{"nctId":"NCT01949129","phase":"PHASE2, PHASE3","title":"Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2013-04","conditions":"Acute Lymphoblastic Leukaemia","enrollment":1800},{"nctId":"NCT02916979","phase":"PHASE1","title":"Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2016-09-06","conditions":"Leukemia, Lymphoid, Leukemia, Myeloid, Myelodysplastic Syndromes","enrollment":20},{"nctId":"NCT03096782","phase":"PHASE2","title":"Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-10-13","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia","enrollment":6},{"nctId":"NCT05293509","phase":"PHASE2","title":"Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-02","conditions":"Stem Cell Transplantation","enrollment":""},{"nctId":"NCT03513328","phase":"PHASE1, PHASE2","title":"Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation","status":"COMPLETED","sponsor":"University of Florida","startDate":"2018-06-15","conditions":"Bone Marrow Failure Syndrome, Thalassemia, Sickle Cell Disease","enrollment":6},{"nctId":"NCT01044745","phase":"PHASE2","title":"Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2009-12-10","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission","enrollment":20},{"nctId":"NCT01860170","phase":"PHASE1, PHASE2","title":"Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis","status":"COMPLETED","sponsor":"Corewell Health West","startDate":"2012-04","conditions":"Hematological Malignancy","enrollment":28},{"nctId":"NCT03035422","phase":"NA","title":"Sequential Conditioning in Haploidentical Transplantation for Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Association for Training, Education, and Research in Hematology, Immunology, and Transplantation","startDate":"2018-01-15","conditions":"Refractory Acute Myeloid Leukemia","enrollment":24},{"nctId":"NCT03412266","phase":"PHASE2","title":"RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2018-02-01","conditions":"Myelodysplastic Syndromes","enrollment":50},{"nctId":"NCT03600909","phase":"PHASE2","title":"A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-05-15","conditions":"Fanconi Anemia, Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML)","enrollment":3},{"nctId":"NCT02083250","phase":"PHASE1","title":"Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-03-06","conditions":"Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Allogeneic Hematopoietic Stem Cell Transplantation Recipient","enrollment":70},{"nctId":"NCT01471444","phase":"PHASE3","title":"Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-11-02","conditions":"Disorder Related to Bone Marrow Transplantation, Leukemia, Transplantation Infection","enrollment":256},{"nctId":"NCT01131169","phase":"PHASE2","title":"Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2010-05","conditions":"Multiple Myeloma","enrollment":66},{"nctId":"NCT01020539","phase":"PHASE1","title":"Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia","status":"COMPLETED","sponsor":"Columbia University","startDate":"2002-09-11","conditions":"Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Juvenile Myelomonocytic Leukemia","enrollment":18},{"nctId":"NCT02129582","phase":"PHASE1","title":"Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2014-11-05","conditions":"Acute Myeloid Leukemia, Hematologic Malignancies, Acute Lymphocytic Leukemia","enrollment":14},{"nctId":"NCT00813124","phase":"PHASE2","title":"Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-12","conditions":"Stem Cell Transplantation, Leukemia","enrollment":24},{"nctId":"NCT00943800","phase":"NA","title":"Combined Haploidentical-Cord Blood Transplantation for Adults and Children","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2006-10-09","conditions":"Leukemia, Myelodysplastic Syndrome, Multiple Myeloma","enrollment":87},{"nctId":"NCT00469014","phase":"PHASE2","title":"Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-09","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia","enrollment":72},{"nctId":"NCT02876679","phase":"PHASE2","title":"Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-04-06","conditions":"Graft vs Host Disease","enrollment":94},{"nctId":"NCT00822770","phase":"PHASE1, PHASE2","title":"Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-01","conditions":"Stem Cell Transplantation, Leukemia","enrollment":47},{"nctId":"NCT03955601","phase":"PHASE2","title":"A Novel TBI Free Conditioning Protocol for Haploidentical Transplant in Acquired Aplastic Anemia:","status":"UNKNOWN","sponsor":"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan","startDate":"2018-07-12","conditions":"Aplastic Anemia Idiopathic","enrollment":30},{"nctId":"NCT03821987","phase":"NA","title":"Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2018-12-17","conditions":"Aplastic Anemia, Stem Cell Transplant Complications, Engraft Failure","enrollment":55},{"nctId":"NCT00498316","phase":"PHASE1","title":"Cord Blood Expansion on Mesenchymal Stem Cells","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-07-03","conditions":"Myelodysplastic Syndrome, Leukemia","enrollment":98},{"nctId":"NCT00475020","phase":"PHASE2","title":"Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-01-04","conditions":"Myelofibrosis","enrollment":63},{"nctId":"NCT02627573","phase":"PHASE2","title":"Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT","status":"TERMINATED","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2015-07","conditions":"Leukemia, Chronic Myeloid, Myelodysplastic Syndromes, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative","enrollment":32},{"nctId":"NCT01279616","phase":"PHASE2","title":"A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease","status":"TERMINATED","sponsor":"Nationwide Children's Hospital","startDate":"2010-09","conditions":"Sickle Cell Disease","enrollment":8},{"nctId":"NCT00801931","phase":"PHASE1, PHASE2","title":"Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders","status":"TERMINATED","sponsor":"Columbia University","startDate":"2007-09-06","conditions":"Leukemia, Lymphoma, Neuroblastoma","enrollment":1},{"nctId":"NCT02483325","phase":"PHASE2","title":"Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases","status":"COMPLETED","sponsor":"Institut Paoli-Calmettes","startDate":"2014-09","conditions":"Hematological Diseases","enrollment":33},{"nctId":"NCT01499147","phase":"NA","title":"Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2000-02","conditions":"Acute Myeloid Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia","enrollment":100},{"nctId":"NCT01049854","phase":"PHASE2","title":"CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant","status":"COMPLETED","sponsor":"New York Medical College","startDate":"2011-09","conditions":"Leukemia, Lymphoma, Bone Marrow Failure","enrollment":20},{"nctId":"NCT02428517","phase":"","title":"Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia (2015)","status":"TERMINATED","sponsor":"Asan Medical Center","startDate":"2015-04","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":20},{"nctId":"NCT01037764","phase":"PHASE2","title":"Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Asan Medical Center","startDate":"2010-01","conditions":"Acute Lymphoid Leukemia","enrollment":100},{"nctId":"NCT00070135","phase":"PHASE2","title":"Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2004-01","conditions":"Adult Acute Myeloid Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","enrollment":121},{"nctId":"NCT01572181","phase":"PHASE2","title":"Study of a Reduced-toxicity Myeloablative Conditioning Regimen Using Fludarabine and Full Doses of Intravenous Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2012-04","conditions":"Hematologic Malignancy","enrollment":50},{"nctId":"NCT01565616","phase":"PHASE2","title":"Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease","status":"COMPLETED","sponsor":"Emory University","startDate":"2012-03","conditions":"Sickle Cell Disease","enrollment":22},{"nctId":"NCT03246178","phase":"NA","title":"Haploidentical Transplantation in Severe Aplastic Anemia","status":"UNKNOWN","sponsor":"Wu Xiaoxiong","startDate":"2017-07-10","conditions":"Severe Aplastic Anemia","enrollment":60},{"nctId":"NCT00448357","phase":"PHASE1, PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2005-10","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":54},{"nctId":"NCT00691015","phase":"PHASE2","title":"Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2008-05","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":48},{"nctId":"NCT03190733","phase":"PHASE4","title":"A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2017-08-30","conditions":"Chronic Graft-versus-host-disease, Leukemia Relapse","enrollment":192},{"nctId":"NCT01158118","phase":"PHASE2","title":"Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2011-04-01","conditions":"Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Lymphoma, Non-Hodgkin","enrollment":48},{"nctId":"NCT03171831","phase":"PHASE4","title":"Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2017-04-01","conditions":"Thalassemia Major","enrollment":30},{"nctId":"NCT02472392","phase":"PHASE1","title":"Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma","status":"COMPLETED","sponsor":"University of Louisville","startDate":"2013-04","conditions":"EWINGS SARCOMA","enrollment":10},{"nctId":"NCT01471067","phase":"PHASE1","title":"Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-07-13","conditions":"Blood And Marrow Transplantation, Leukemia, Lymphoma","enrollment":33},{"nctId":"NCT01534143","phase":"PHASE2","title":"High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant","status":"TERMINATED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2012-02","conditions":"Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma","enrollment":1},{"nctId":"NCT01621477","phase":"PHASE2","title":"T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2012-08","conditions":"Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Myelocytic Leukemia","enrollment":34},{"nctId":"NCT00670410","phase":"PHASE1","title":"Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma","status":"TERMINATED","sponsor":"Columbia University","startDate":"2003-11","conditions":"Neuroblastoma","enrollment":15},{"nctId":"NCT02784561","phase":"PHASE4","title":"Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2016-07","conditions":"Leukemia","enrollment":80},{"nctId":"NCT01056614","phase":"PHASE2","title":"Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2004-09","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities","enrollment":23},{"nctId":"NCT01390402","phase":"PHASE2","title":"Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-01","conditions":"Leukemia, Chronic Myelogenous Leukemia","enrollment":6},{"nctId":"NCT00582933","phase":"PHASE2","title":"Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2001-05","conditions":"Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma","enrollment":96},{"nctId":"NCT00874315","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.","status":"WITHDRAWN","sponsor":"Nationwide Children's Hospital","startDate":"2008-09","conditions":"Neuroblastoma","enrollment":""},{"nctId":"NCT00402558","phase":"PHASE1","title":"Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-05","conditions":"Myelodysplastic Syndrome, Leukemia","enrollment":15},{"nctId":"NCT00916045","phase":"PHASE2","title":"Pilot Study of Unrelated Cord Blood Transplantation","status":"TERMINATED","sponsor":"King's College Hospital NHS Trust","startDate":"2009-09","conditions":"Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Leukemia, Lymphoblastic, Acute","enrollment":40},{"nctId":"NCT00885833","phase":"PHASE1, PHASE2","title":"Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS)","status":"COMPLETED","sponsor":"The Korean Society of Pediatric Hematology Oncology","startDate":"2007-02","conditions":"Wiskott-Aldrich Syndrome","enrollment":5},{"nctId":"NCT01786018","phase":"PHASE2","title":"Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas","status":"UNKNOWN","sponsor":"Azienda Ospedaliera San Giovanni Battista","startDate":"2013-02","conditions":"B-cell Lymphoma Refractory","enrollment":42},{"nctId":"NCT01622556","phase":"PHASE2","title":"Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies","status":"TERMINATED","sponsor":"University of Virginia","startDate":"2012-01","conditions":"Hematologic Malignancies","enrollment":6},{"nctId":"NCT00396968","phase":"PHASE1, PHASE2","title":"AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS","status":"WITHDRAWN","sponsor":"Genzyme, a Sanofi Company","startDate":"","conditions":"Acute Myelogenous Leukemia, Myelodysplastic Syndromes","enrollment":""},{"nctId":"NCT01455506","phase":"PHASE1","title":"PRO#0118: Decitabine Plus Mini Flu-Bu","status":"COMPLETED","sponsor":"Hackensack Meridian Health","startDate":"2009-05","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":20},{"nctId":"NCT00679536","phase":"PHASE1, PHASE2","title":"Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors","status":"UNKNOWN","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2008-05","conditions":"Leukemia","enrollment":30},{"nctId":"NCT00894049","phase":"PHASE2","title":"A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation","status":"COMPLETED","sponsor":"Institut Paoli-Calmettes","startDate":"2002-11","conditions":"Allograft, Allogeneic Cell Transplantaion, Hematological Malignancy","enrollment":148},{"nctId":"NCT01983761","phase":"PHASE1, PHASE2","title":"Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation","status":"UNKNOWN","sponsor":"Targazyme, Inc.","startDate":"2013-11","conditions":"Blood And Marrow Transplantation, Leukemia, Lymphoma","enrollment":25},{"nctId":"NCT00795132","phase":"PHASE2","title":"Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"University of Utah","startDate":"2004-04","conditions":"Acute Leukaemia, Chronic Disease, Leukemia","enrollment":47},{"nctId":"NCT00787761","phase":"PHASE2","title":"Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer","status":"COMPLETED","sponsor":"Northside Hospital, Inc.","startDate":"2007-04","conditions":"Myeloproliferative Disorders, Kidney Cancer, Leukemia","enrollment":24},{"nctId":"NCT01087398","phase":"PHASE2, PHASE3","title":"Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis","status":"UNKNOWN","sponsor":"Tehran University of Medical Sciences","startDate":"2009-09","conditions":"Osteopetrosis","enrollment":10},{"nctId":"NCT01238328","phase":"PHASE2, PHASE3","title":"Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis","status":"UNKNOWN","sponsor":"Tehran University of Medical Sciences","startDate":"2009-09","conditions":"Mucopolysaccharidosis","enrollment":10},{"nctId":"NCT00841724","phase":"PHASE2","title":"Study of a Reduced-toxicity \"Submyeloablative\" Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2009-01","conditions":"Hematological Malignancies","enrollment":82},{"nctId":"NCT00499889","phase":"PHASE2","title":"Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2003-02","conditions":"Leukemia","enrollment":42},{"nctId":"NCT00887042","phase":"PHASE1, PHASE2","title":"Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML","status":"UNKNOWN","sponsor":"The Korean Society of Pediatric Hematology Oncology","startDate":"2006-06","conditions":"Acute Myeloid Leukemia","enrollment":35},{"nctId":"NCT00915811","phase":"PHASE2","title":"Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin","status":"TERMINATED","sponsor":"King's College Hospital NHS Trust","startDate":"2007-06","conditions":"Myelodysplastic Syndromes, Leukemia, Myeloid, Acute","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":40,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Fludarabine, Busulfan, Thymoglobulin","genericName":"Fludarabine, Busulfan, Thymoglobulin","companyName":"The Korean Society of Pediatric Hematology Oncology","companyId":"the-korean-society-of-pediatric-hematology-oncology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fludarabine is a purine analog that interferes with DNA synthesis, Busulfan is an alkylating agent that cross-links DNA, and Thymoglobulin is a monoclonal antibody that depletes T-lymphocytes. Used for Acute myeloid leukemia, Chronic lymphocytic leukemia, Kidney transplant rejection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}